Health care stocks have turned around and were posting moderate gains in recent trade, with the NYSE Health Care Index rising about 0.1% while shares of health care companies in the S&P 500 were up almost 0.4% as a group. In company news, Bellerophon Therapeutics (BLPH) slumped Friday after the early-stage cardiopulmonary therapeutics company said its iNOpulse inhaler device appears to have no impact on systemic blood pressures, heart rates or respiratory rates in patients with pulmonary arterial hypertension before or after exercise.
In a poster presentation last night at an industry conference in San Diego, the company said its investigator-led study found nitric oxide inhaled through its iNO pulse device may allow for increases in exercise capacity and may have a role in the long term treatment of these patients.
The researchers did not observe any significant negative effects on patients using the device, the company said, although there also was no apparent effect on heart and breathing rates or blood pressure, according to the company. Phase III testing of the iNOphase device is ongoing, with interim results expected by the end of the year and top-line results targeted for mid-2018.